NCT06234462WithdrawnPhase 2
A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
Feasibility Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid: A Pilot Randomized Control Trial
Source: ClinicalTrials.gov · Last updated 26 Aug 2025
Reason given: challenges with recruitment
Brief summary (registry, in English)
Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.
- Status (registry)
- Withdrawn
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 8 Jan 2024
- Start date
- Jun 2025
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- University of Texas Southwestern Medical Center
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06234462
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity to amantadine
- Clinically significant psychiatric, neurologic, renal, hepatic, opthalmologic, cardiac impairment in the opinion of the investigators, including but not limited to:
- Psychiatric:
- Acute or chronic unstable Axis I psychiatric illness
- History of psychosis
- Epilepsy
- Cognitive dysfunction predating COVID infection
- History of delirium
- Neurologic conditions with agitation or confusion
Other
- Severe depression Patient Health Questionnaire-9 (PHQ-9) score >= 20
- Suicidality
- Neurologic:
Who the study is looking for
- Age 20-65
- Can provide informed consent
- Confirmed COVID+ test (either rapid antigen or PCR) between 8 weeks and one year prior to initial visit.
- Able to consent in English
- Endorse symptoms during their initial evaluation and history with the provider that began around the time of the acute COVID19 infection (subjective) including cognitive changes such as cognitive fatigue, brain fog, memory issues,attention issues AND have symptoms in at least 1 out of the 2 following symptom categories:
- Category 1: Decreased endurance, physical fatigue, weakness
- Category 2: Depression, anxiety
Age in the registry: 20 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UT Southwestern Medical Center | Dallas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.